NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Hemispherian AS

Hemispherian AS

Private
OsloHealthcare & Life Scienceshttps://www.hemispherian.com/

Last Round

Joint Venture

Sep 29, 2025

Total Funding Raised

$10.04M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Hemispherian AS is a clinical-stage pharmaceutical company developing a novel class of small molecule drugs that target the TET2 enzyme to treat aggressive cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

small-molecule therapeuticsoncologyglioblastoma treatmentepigenetic cancer therapyTET2 enzymedrug discovery platformbiotechclinical-stage pharmaDNA damagecancer drug developmentorphan drugclinical trialsgliomaprecision oncologytargeted therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hemispherian AS Comparables

Compare Hemispherian AS with similar companies based on industry and business-model similarity.

Hemispherian AS comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Curtana Pharmaceuticals
85%
Oniria Therapeutics
83%
EPICS Therapeutics
82%

Hemispherian AS Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Joint VentureSep 29, 2025
GrantDec 15, 2023
Series ANov 24, 2022
VC RoundOct 19, 2022
GrantOct 19, 2022
Seed
May 3, 2022

Key People

Founding team and executive leadership

Zeno Albisser

Chief Executive Officer

Executive Team

Terezia Prikrylova

Chief Operating Officer

Executive Team

Hemispherian AS Investors

Notable investors and investment history

Hemispherian AS investors
InvestorRounds
European Innovation Council FundGrant
European CommissionGrant
KistefosSeries A
InvestinorSeed
MeneldorSeed, Series A
KvantiaSeries A
The Research Council of NorwayGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Monthly visitors increased 343% MoM.

  • Sep 29, 2025

    Completed a joint venture funding round.

Hemispherian AS Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hemispherian AS Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hemispherian AS's valuation, stock price, and market status.

Firmographic Details

HeadquartersOslo
Employee Range9
Year Founded2015
Last FundingSep 29, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.